Quality-control issues and approaches in vaccine development

References

• Buckland BC. The process development challenge for a new vaccine. Nat. Med.11(4), S16–S19 (2005).
   PubMedGoogle Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis.47(3), 401–409 (2008).
   PubMed Web of Science ®Google Scholar
• Peter G, des Vignes-Kendrick M, Eickhoff TC et al. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics104(4 Pt 1), 942–950 (1999).
   PubMed Web of Science ®Google Scholar
• Sheridan C. The business of making vaccines. Nat. Biotechnol.23(11), 1359–1366 (2005).
   PubMed Web of Science ®Google Scholar
• ICH guideline Q7. Good manufacturing practice for active pharmaceutical ingredients. 1–49 (2000).
   Google Scholar
• ICH guideline Q9. Quality risk management. 1–19 (2005).
   Google Scholar
• ICH guideline Q8. Pharmaceutical development. 1–9 (2006).
   Google Scholar
• Dellepiane N, Griffiths E, Milstien JB. New challenges in assuring vaccine quality. Bull. World Health Organ.78(2), 155–162 (2000).
   PubMed Web of Science ®Google Scholar
• Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ. Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev. Vaccines4(6), 855–866 (2005).
   PubMed Web of Science ®Google Scholar
• Capelle MA, Brugger P, Arvinte T. Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: correlation with antibody vaccine immunogenicity. Vaccine23(14), 1686–1694 (2005).
   PubMed Web of Science ®Google Scholar
• Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J. Biol. Chem.280(14), 13406–13414 (2005).
   PubMed Web of Science ®Google Scholar
• Peek LJ, Martin TT, Elk Nation C, Pegram SA, Middaugh CR. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J. Pharm. Sci.96(3), 547–557 (2007).
   PubMed Web of Science ®Google Scholar
• Edwards KM. Development, acceptance, and use of immunologic correlates of protection in monitoring the effectiveness of combination vaccines. Clin. Infect. Dis.33(Suppl. 4), S274–S277 (2001).
   PubMed Web of Science ®Google Scholar
• Taffs RE. Potency tests of combination vaccines. Clin. Infect. Dis.33(Suppl. 4), S362–S366 (2001).
   Google Scholar
• Postema AS, Myers MG, Breiman RF. Challenges in the development, licensure, and use of combination vaccines. Clin. Infect. Dis.33(Suppl. 4), S261–S266 (2001).
   PubMed Web of Science ®Google Scholar
• Gnanashanmugam D, Falkovitz-Halpern MS, Dodge A et al. Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay. J. Clin. Microbiol.45(8), 2419–2425 (2007).
   PubMed Web of Science ®Google Scholar
• Lu Z, Douthitt MP, Taffs RE, Ran Y, Norwood LP, Chumakov KM. Quantitative aspects of the mutant analysis by PCR and restriction enzyme cleavage (MAPREC). PCR Methods Appl.3(3), 176–180 (1993).
   PubMedGoogle Scholar
• Diphtheria vaccine (adsorbed). In: Monograph 0443. European Pharmacopeia Commission (5th Edition).660–661. Council of Europe, Strasbourg, France (2005).
   Google Scholar
• Schalk JA, de Vries CG, Jongen PM. Potency estimation of measles, mumps and rubella trivalent vaccines with quantitative PCR infectivity assay. Biologicals33(2), 71–79 (2005).
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Reddin KM, Funnell SG, Johansson L, Rytkonen A, Jonsson AB. Experimental disease models for the assessment of meningococcal vaccines. Vaccine23(17–18), 2214–2217 (2005).
   PubMed Web of Science ®Google Scholar
• Mrkic B, Pavlovic J, Rulicke T et al. Measles virus spread and pathogenesis in genetically modified mice. J. Virol.72(9), 7420–7427 (1998).
   PubMed Web of Science ®Google Scholar
• Johansson L, Rytkonen A, Bergman P et al. CD46 in meningococcal disease. Science301(5631), 373–375 (2003).
   PubMed Web of Science ®Google Scholar
• Nomura T, Tamaoki N, Takakura A, Suemizu H. Basic concept of development and practical application of animal models for human diseases. Curr. Top. Microbiol. Immunol.324, 1–24 (2008).
   PubMed Web of Science ®Google Scholar
• Lal G, Balmer P, Joseph H, Dawson M, Borrow R. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin. Diagn. Lab. Immunol.11(2), 272–279 (2004).
   PubMedGoogle Scholar
• Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J. Immunol. Methods296(1–2), 135–147 (2005).
   PubMed Web of Science ®Google Scholar
• Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum. Vaccin.4(2), 134–142 (2008).
   PubMed Web of Science ®Google Scholar
• van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J. Immunol. Methods335(1–2), 79–89 (2008).
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet2(8346), 355–357 (1983).
   PubMed Web of Science ®Google Scholar
• Alaedini A, Latov N. Antibodies against OspA epitopes of Borrelia burgdorferi cross-react with neural tissue. J. Neuroimmunol.159(1–2), 192–195 (2005).
   PubMed Web of Science ®Google Scholar
• Arigita C, Kersten GF, Hazendonk T, Hennink WE, Crommelin DJ, Jiskoot W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine21(9–10), 950–960 (2003).
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89(4), 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364(9431), 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Crotty S, Ahmed R. Immunological memory in humans. Semin. Immunol.16(3), 197–203 (2004).
   PubMed Web of Science ®Google Scholar
• Kelly DF, Pollard AJ, Moxon ER. Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA294(23), 3019–3023 (2005).
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Oh S, Hamaluba M, Westcar S, Beverley PC, Pollard AJ. Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin. Vaccine Immunol.15(2), 182–193 (2008).
   PubMedGoogle Scholar
• Nanan R, Heinrich D, Frosch M, Kreth HW. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. Vaccine20(3–4), 498–504 (2001).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med.309(1), 13–17 (1983).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med.11(4 Suppl.), S33–S44 (2005).
   PubMed Web of Science ®Google Scholar
• Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A73(11), 975–983 (2008).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol.176(10), 6333–6339 (2006).
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol.8(4), 247–258 (2008).
   PubMed Web of Science ®Google Scholar
• US FDA. Guidance for Industry. PAT – A framework for innovative pharmaceutical development, manufacturing, and quality assurance. US Food and Drug Administration, 1–19 (2004).
   Google Scholar
• Streefland M, van de Waterbeemd B, Happe H et al. PAT for vaccines: the first stage of PAT implementation for development of a well-defined whole-cell vaccine against whooping cough disease. Vaccine25(16), 2994–3000 (2007).
   PubMed Web of Science ®Google Scholar
• Streefland M, van de Waterbeemd B, Kint J et al. Evaluation of a critical process parameter: oxygen limitation during cultivation has a fully reversible effect on gene expression of Bordetella pertussis. Biotechnol. Bioeng.102(1), 161–167 (2008).
   Web of Science ®Google Scholar
• Metz B, Jiskoot W, Hennink WE, Crommelin DJ, Kersten GF. Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines. Vaccine22(2), 156–167 (2003).
   PubMed Web of Science ®Google Scholar
• Metz B, Jiskoot W, Mekkes D et al. Quality control of routine, experimental and real-time aged diphtheria toxoids by in vitro analytical techniques. Vaccine25(39–40), 6863–6871 (2007).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Vaccine development for an imminent pandemic: why we should worry, what we must do. Hum. Vaccin.2(1), 38–42 (2006).
   PubMed Web of Science ®Google Scholar
• EMEA. Committee for medicinal products for human use (CHMP).Guideline on strategies to idenitfy and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07 (2007).
   Google Scholar
• Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med.355(10), 1018–1028 (2006).
   PubMed Web of Science ®Google Scholar
• Farrington C, Miller E. Meningococcal vaccine trials. In: Methods in Molecular Medicine: Meningococcal Vaccines. Pollard AJ, Maiden MCJ (Eds). Humana Press, NJ, USA 371–393 (2001).
   Google Scholar
• WHO. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series 927, Annex 2 (2005).
   Google Scholar
• EMEA. Committee for medicinal products for human use (CHMP). Guideline on clinical evaluation of new vaccines. EMEA/CHMP/SWP/164653/2005 (2006).
   Google Scholar
• European Pharmacopeia Commission. Edition 6.3. Council of Europe, Strasbourg (2009).
   Google Scholar
• WHO. Recommendations for diphtheria, tetanus, pertussis and combined vaccines. WHO technical report series, No. 927, Annex 5 (2003).
   Google Scholar
• Akkermans AM, Hendriksen CF, Marsman FR, van de Donk HJ. Evaluation and validation of a single-dilution potency assay based upon serology of vaccines containing diphtheria toxoid: analysis for consistency in production and testing. Dev. Biol. Stand.86, 323–324 (1996).
   PubMedGoogle Scholar
• Quality risk management. In: Eudralex (Volume 4); EU guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinairy Use. Annex 20 (2008).
   Google Scholar
• ICH Topic Q2. Validation of analytical procedures: text and methodology (2005).
   Google Scholar
• US FDA. Guidance for Industry. Investigating out-of-specification (OOS) test results for pharmaceutical production. 1–14. US Food and Drug Administration (2006).
   Google Scholar
• Shewhart WA. Statistical method from the viewpoint of quality control. The Graduate School, the Department of agriculture, WA, USA (1939).
   Google Scholar
• Meiring HD, Soethout EC, de Jong AP, van Els CA. Targeted identification of infection-related HLA class I-presented epitopes by stable isotope tagging of epitopes (SITE). Curr. Protoc. Immunol. Chapter 16, Unit 16 13 (2007).
   Google Scholar
• Wu XD, Kircher RA, McVerry PH, Malinzak DA. Characterization of post-translationally modified recombinant protein using liquid chromatography/mass spectrometry. Dev. Biol. (Basel)103, 61–67 (2000).
   PubMedGoogle Scholar
• Williams JN, Skipp PJ, Humphries HE, Christodoulides M, O’Connor CD, Heckels JE. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect. Immun.75(3), 1364–1372 (2007).
   PubMed Web of Science ®Google Scholar
• Turula VE, Kim J, Michon F, Pankratz J, Zhang Y, Yoo C. An integrity assay for a meningococcal type B conjugate vaccine. Anal. Biochem.327(2), 261–270 (2004).
   PubMed Web of Science ®Google Scholar
• Mawas F, Ho MM, Huskisson R, Saydam M, Corbel MJ. Physico-chemical characterisation and immunogenicity of a multi-valent candidate vaccine against non-typeable Haemophilus influenzae and Moraxella catarrhalis.Vaccine25(25), 4801–4808 (2007).
   PubMed Web of Science ®Google Scholar
• Frech C, Hilbert AK, Hartmann G, Mayer K, Sauer T, Bolgiano B. Physicochemical analysis of purified diphtheria toxoids: is toxoided then purified the same as purified then toxoided? Dev. Biol. (Basel)103, 205–215 (2000).
   PubMedGoogle Scholar
• Rich RL, Myszka DG. Spying on HIV with SPR. Trends Microbiol.11(3), 124–133 (2003).
   PubMed Web of Science ®Google Scholar
• Turbyfill KR, Kaminski RW, Oaks EV. Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. Vaccine26(10), 1353–1364 (2008).
   PubMed Web of Science ®Google Scholar
• Jiang G, Joshi SB, Peek LJ et al. Anthrax vaccine powder formulations for nasal mucosal delivery. J. Pharm. Sci.95(1), 80–96 (2006).
   PubMed Web of Science ®Google Scholar
• Amorij JP, Meulenaar J, Hinrichs WL et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine25(35), 6447–6457 (2007).
   PubMed Web of Science ®Google Scholar
• Jedrzejas MJ, Lamani E, Becker RS. Characterization of selected strains of pneumococcal surface protein A. J. Biol. Chem.276(35), 33121–33128 (2001).
   PubMed Web of Science ®Google Scholar
• Salnikova MS, Joshi SB, Rytting JH, Warny M, Middaugh CR. Physical characterization of Clostridium difficile toxins and toxoids: effect of the formaldehyde crosslinking on thermal stability. J. Pharm. Sci.97(9), 3735–3752 (2008).
   PubMed Web of Science ®Google Scholar
• Belnap DM, McDermott BM Jr, Filman DJ et al. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl Acad. Sci. USA97(1), 73–78 (2000).
   PubMed Web of Science ®Google Scholar
• Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine14(10), 1001–1008 (1996).
   PubMed Web of Science ®Google Scholar
• Lorent E, Bierau H, Engelborghs Y, Verheyden G, Bosman F. Structural characterisation of the hepatitis C envelope glycoprotein E1 ectodomain derived from a mammalian and a yeast expression system. Vaccine26(3), 399–410 (2008).
   PubMed Web of Science ®Google Scholar
• McHugh CA, Tammariello RF, Millard CB, Carra JH. Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein Sci.13(10), 2736–2743 (2004).
   PubMed Web of Science ®Google Scholar
• Zheng Y, Lai X, Bruun SW et al. Determination of moisture content of lyophilized allergen vaccines by NIR spectroscopy. J. Pharm. Biomed. Anal.46(3), 592–596 (2008).
   PubMed Web of Science ®Google Scholar
• Lai X, Zheng Y, Sondergaard I et al. Determination of aluminium content in aluminium hydroxide formulation by FT-NIR transmittance spectroscopy. Vaccine25(52), 8732–8740 (2007).
   PubMed Web of Science ®Google Scholar
• Lamb DH, Summa L, Lei QP. Capillary electrophoretic analysis of meningococcal polysaccharide–diphtheria toxoid conjugate vaccines. Dev. Biol. (Basel)103, 251–258 (2000).
   PubMedGoogle Scholar
• Mellado MC, Franco C, Coelho A, Alves PM, Simplicio AL. Sodium dodecyl sulfate-capillary gel electrophoresis analysis of rotavirus-like particles. J. Chromatogr. A1192(1), 166–172 (2008).
   PubMed Web of Science ®Google Scholar
• Stewart-Tull DE, Bleakley CR, Galloway TS. Characteristics of Vibrio cholerae proteinases: potential, candidate vaccine antigens. Vaccine22(23–24), 3026–3034 (2004).
   PubMed Web of Science ®Google Scholar
• Delgado M, Yero D, Niebla O et al. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate. Vaccine25(50), 8420–8431 (2007).
   PubMed Web of Science ®Google Scholar
• Khemiri A, Galland A, Vaudry D et al. Outer-membrane proteomic maps and surface-exposed proteins of Legionella pneumophila using cellular fractionation and fluorescent labelling. Anal. Bioanal. Chem.390(7), 1861–1871 (2008).
   PubMed Web of Science ®Google Scholar
• Smith TG, Lim JM, Weinberg MV, Wells L, Hoover TR. Direct analysis of the extracellular proteome from two strains of Helicobacter pylori. Proteomics7(13), 2240–2245 (2007).
   PubMed Web of Science ®Google Scholar
• Metz B, Kersten GF, Baart GJ et al. Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug. Chem.17(3), 815–822 (2006).
   PubMed Web of Science ®Google Scholar
• Davidsen J, Rosenkrands I, Christensen D et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6´-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta1718(1–2), 22–31 (2005).
   PubMed Web of Science ®Google Scholar
• Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. J. Pharm. Sci.96(12), 3155–3167 (2007).
   PubMed Web of Science ®Google Scholar